TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Sodium Nitrite on Heart Failure With Preserved Ejection Fraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Heart Failure with preserved Ejection Fraction (HFpEF) is defined by clinical symptoms of dyspnea and fatigue~* Normal left ventricular ejection fraction (\>/=50%)~* And elevated Left Ventricular (LV) filling pressure at cardiac catheterization (defined as resting Pulmonary Capillary Wedge Pressure (PCWP)\>15 mmHg and/or PCWP \>/=25 mmHg during exercise).~Exclusion Criteria:~* Systolic Blood Pressure \<120 mmHg (during catheterization)~* Prior nitrate therapy (within previous 2 weeks)~* Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency~* Other non-HFpEF specific causes of heart failure such as significant valvular disease (\>moderate left-sided regurgitation, \>mild stenosis)~* Severe pulmonary disease~* Unstable coronary disease or coronary spasm~* Primary renal or hepatic disease (end stage renal failure/on dialysis or clinical diagnosis of hepatitis or hepatic cirrhosis)~* Constrictive pericarditis, or infiltrative, restrictive, or hypertrophic cardiomyopathies~* Pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Saline) (Type: PLACEBO_COMPARATOR): Participants receive normal saline, administered by inhalation over 10-15 minutes, using a nebulizer
- Sodium Nitrite (Type: EXPERIMENTAL): Participants receive Sodium Nitrite inhalation solution, administered by inhalation over 10-15 minutes, using a nebulizer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Motivated Behavior in Adults With and Without ADHD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. generally healthy~2. between the ages of 18-45~3. non-ADHD subjects do not meet criteria for ADHD diagnosis or any subtype as determined by the Conners Diagnostic Interview or any T-Score \> 55 on Inattentive Symptoms, Hyperactive-Impulsive Symptoms, Total Symptoms or ADHD Index subscales of the CAARS.~4. ADHD subjects meet criteria for a primary diagnosis of ADHD, any subtype, based on DSM-5~Exclusion Criteria:~1. inability to attend all required experimental sessions~2. significant health problems (e.g., current and uncontrolled liver, lung, or heart problems, current or past seizure disorder, serious head trauma)~3. primary diagnosis of Axis I psychiatric disorders other than ADHD (e.g., depression, anxiety disorder, schizophrenia)~4. meet DSM-5 criteria for substance use disorder other than nicotine in the past 12 months~5. use of psychoactive medications in the past 6 months as indicated by self-report~6. positive urine drug screen for drugs or positive breath alcohol concentration~7. contraindications for MPH~8. among women, nursing or a positive pregnancy test~9. IQ \< 80 on Kaufman Brief Intelligence Test, 2nd edition~10. allergy to lactose~11. hypertension (If subject is ≤ 40 years of age and has blood pressure over 135/85 or heart rate over 90 beats per minute. If subject is \> 40 years of age and has blood pressure over 130/80 or heart rate over 88 beats per minute)~12. body mass ratio \> 30

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- ADHD group (Type: EXPERIMENTAL): Adults with ADHD
- non-ADHD group (Type: EXPERIMENTAL): Adults without ADHD

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Once-Daily Investigational Nasal Spray In Adults And Adolescents With Perennial Allergic Rhinitis (PAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of perennial allergic rhinitis (PAR).~* Must comply with study procedures and be literate.~Exclusion Criteria:~* Significant concomitant medical conditions.~* Use of corticosteroids.~* Use of allergy and other identified medications during the study.~* Current tobacco use or tobacco use within the past year.~* Exposure to an investigational study drug within the past 12 months.~* Clinically significant abnormal electrocardiograms (ECG) or laboratory abnormality.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fluticasone furoate (Type: EXPERIMENTAL): Participants were instructed to administer two sprays into each nostril once daily every morning of fluticasone furoate 110 μg
- Placebo (Type: PLACEBO_COMPARATOR): Participants were instructed to administer two sprays into each nostril once daily every morning of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate CORT125134 in Participants With Cushing's Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has a confirmed diagnosis of endogenous Cushing's syndrome.~2. Requires medical treatment of hypercortisolemia.~3. Meets at least one of the following criteria:~   1. Has type 2 diabetes mellitus.~  2. Has impaired glucose tolerance.~  3. Has hypertension.~Exclusion Criteria:~1. Has non-endogenous source of hypercortisolemia~2. Has uncontrolled, clinically significant hypothyroidism or hyperthyroidism~3. Has poorly controlled hypertension~4. Has Stage ≥ 4 renal failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Group 1: Low-dose Group (Type: EXPERIMENTAL): 100 mg/day for 4 weeks in Period 1, then 150 mg/day for 4 weeks in Period 2, then 200 mg/day for 4 weeks in Period 3. There was no washout between treatment periods. Period 3 was followed by a 4-week follow-up period. Per-protocol, Group 1 did not participate in treatment Period 4.
- Group 2: High-dose Group (Type: EXPERIMENTAL): 250 mg/day for 4 weeks in Period 1, then 300 mg/day for 4 weeks in Period 2, then 350 mg/day for 4 weeks in Period 3, then 400 mg/day for 4 weeks in Period 4. There was no washout between treatment periods. Period 4 was followed by a 4-week follow-up period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy Followed by Surgery in Treating Patients With Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven stage IIIA non-small cell lung cancer (NSCLC)(including squamous, adenocarcinoma, large cell, and poorly differentiated NSCLC) Nodal metastases of T1-3 N2 M0 No distant metastases~PATIENT CHARACTERISTICS: Age: 18 to 75 Performance Status: WHO 0-2 Life Expectancy: Not specified Hematopoietic: Leucocytes greater than 4,000/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin within normal limits AST or ALT no greater than 1.5 times upper limit of normal (ULN) Alkaline phosphatase no greater than 2.5 times ULN Renal: Creatinine clearance greater than 60 mL/min No hypercalcemia Cardiovascular: No unstable cardiac disease No congestive heart failure No angina pectoris No significant arrhythmias No prior history of myocardial infarction within 3 months Pulmonary: Lung function test with a forced expiratory volume greater than 1.2 L/sec Neurologic: No dementia No peripheral neuropathy greater than grade 1 No psychosis No seizure disorders Other: No prior or concurrent malignancies, except: Nonmelanoma skin cancer Carcinoma in situ of the cervix No active uncontrolled infection or other serious medical conditions No diabetes mellitus treated with insulin No gastric ulcers~PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy Chemotherapy: No prior chemotherapy Endocrine therapy: No prior corticosteroids or other endocrine therapy No concurrent treatment with prednisone (except for prophylaxis, treatment of acute hypersensitivity, or chronic treatment initiated greater than 6 months prior to study entry) Radiotherapy: No prior radiotherapy Surgery: No prior surgery for malignancy Other: No concurrent treatment with other experimental drugs No involvement in clinical trials within 30 days of study No prior treatment with other cytostatic therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tenelia Elderly CGMS Study(TEDDY)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who are 65 years or older on screening~* Patients with type 2 diabetes mellitus~* Patients with 7.0% ≤ HbA1c ≤ 9.0% at the screening visit~* Patients with FPG \< 270mg/dL on screening visit~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Teneligliptin (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* 3 or more episodes of acute VVC in the past 12 months~* Positive KOH or Gram stain test~* Total vulvovaginal signs and symptoms score of ≥3 at screening visit~* Total vulvovaginal signs and symptoms score of \<3 at baseline visit~* Must be able to swallow pills~Key Exclusion Criteria:~* Presence or a history of another vaginal or vulvar condition(s)~* Evidence of major organ system disease~* History of cervical cancer~* Poorly controlled diabetes mellitus~* Pregnant~* Recent use of topical or systemic antifungal or antibacterial drugs~* Recent use of immunosuppressive or systemic corticosteroid therapies

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Oteseconazole (VT-1161) 150mg capsule (Type: EXPERIMENTAL): Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks
- Placebo capsule (Type: PLACEBO_COMPARATOR): Once daily for 7 days starting at Day 1, followed by once weekly for 11 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treating Chronic Pain and Depression in HIV+ Patients in Primary Care Settings

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic Pain (pain duration for at least six months with a mean score of 5 or higher on the BPI Pain Interference Scale)~* Pain severity of 40 or higher on a Visual Analog Scale (0-100) indicating worst pain in the last week~* At least one trial of PCP-recommended medication (i.e. acetominophen, NSAIDS, skeletal muscle relaxants) judged through interviews with patients and PCPs~* QIDS score of ≥ 9 (depression severity)~* Stable dose of an antidepressant, if using, for the previous 2 months~* Age 18 or older~* HIV+~Exclusion Criteria:~* Lifetime DSM-IV diagnosis of bipolar disorder, schizophrenia, or other chronic psychotic condition~* Current DSM-IV diagnosis of substance dependence for alcohol, sedative/ hypnotic drugs, stimulants, or cocaine~* Suicidal ideation or behavior requiring immediate attention~* In psychotherapy or in a multidisciplinary pain management program~* Expected surgery in the next 6 months~* Pain thought to be due to cancer, infection, or inflammatory arthritis~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Health Education (Type: PLACEBO_COMPARATOR): Participants in the Health Education arm will receive 7 individual sessions, each of which will focus on a different health education topic.
- HIVPASS Intervention (Type: ACTIVE_COMPARATOR): Participants in the HIVPASS intervention arm will receive 7 individual sessions with the study interventionist, the first of which is a collaborative meeting with the PCP. Sessions will focus on pain interference and depression management.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Ibritumomab Tiuxetan (Zevalin®) in Combination With a Fludarabine-based Reduced Intensity Conditioning (RIC) Regimen (ZEVALLO 2007)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 and ≤ 65~* Patients with this lymphoma:~  1. CD20 positive diffuse large B-cell lymphoma in relapse or refractory after two prior regimens or after one regimen including autologous stem cell transplantation, or~ 2. CD20 positive mantle-cell lymphoma in relapse or refractory after two prior regimens or after one regimen including autologous stem cell transplantation or~ 3. Other CD20 positive aggressive lymphoma for which an indication of allograft is selected (Burkitt lymphoma, lymphoblastic lymphoma, intra-vascular lymphoma.....) or~ 4. Low grade lymphoma CD20 positive (follicular lymphoma, marginal zone lymphoma) in histological processing or~ 5. Low grade lymphoma CD20 positive for which an indication of allograft is selected~* And sensitive to relapse's treatment~* HLA-matched related or unrelated donor 10/10 or 9/10 with C or DQ mismatch without contra-indication for stem cell mobilization~* ECOG (Eastern Cooperative Oncology Group) \< 2~* Having or not received previously rituximab~* With a chemosensitive relapse NHL (at least partial response \> 50% as defined with cheson criteria (See appendix 5)~* Eligible for an allogenic transplant~* With a signed informed consent (obtained on the screening day at the latest and before any investigation)~* Patient affiliated to or beneficiary of the National Health Service~Exclusion Criteria:~* Patient allografted previously~* History of cancer~* Patient with HIV or HCV positive serology and requiring treatment~* Childbearing or child breastfeeding women~* Women who are pregnant or nursing, or man, in the absence of effective contraception during treatment and up to 12 months after stopping treatment~* Any contraindication to allogenic stem cell transplantation:~* Cardiac insufficiency (ejection fraction \< 50% by echocardiography)~* Respiratory insufficiency defined as DLCO below 50% of the theoretical value~* Renal failure defined as creatinin clearance \< 30 ml/mn~* Hepatic failure defined as a 2-fold increase of bilirubin or transaminases except if due to the lymphoma~* Known hypersensitivity to murine antibodies and other proteins, the active ingredients or any of the ingredients of the products under review~* Patient under the protection of justice

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Zevalin (Type: EXPERIMENTAL): Zevalin associated with a Fludarabine-based reduced-intensity conditioning regimen,all patients will receive Zevalin in the conditioning regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Evaluation Of Pregabalin (Lyrica) With Patients With Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis Generalized Anxiety Disorder~* HAM-A score \>=18 and HAM-D (item 1) score \>=2 at screening and baseline~* Needs pharmacological treatment~Exclusion Criteria:~* Current or past diagnosis of any other DSM IV Axis I disorders~* A history of failed treatment with a benzodiazepine~* Any clinically significant, serious, or unstable hematologic, autoimmune, endocrine, cardiovascular, renal, hepatic, gastrointestinal, or neurological disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: EXPERIMENTAL): None
- 4 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe RA according to 2010 American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) joint criteria~* Treatment with tocilizumab SC monotherapy for up to 8 weeks prior to enrollment, under the prescriptive authority of a physician who has made the decision to commence tocilizumab in accordance with the local label~* Methotrexate intolerance, or inadequate response to prior DMARDs and TNF inhibitors where continued methotrexate treatment was deemed inappropriate~Exclusion Criteria:~* Treatment with tocilizumab more than 8 weeks prior to enrollment~* Failure to meet local tocilizumab label indication criteria~* Treatment with any investigational agent within 4 weeks of beginning tocilizumab SC monotherapy~* Last methotrexate dose within 1 week of beginning tocilizumab SC monotherapy~* History of any other autoimmune or joint inflammatory disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab for RA in Routine Clinical Practice (Type: None): Participants from routine clinical practice in Hungary who are receiving treatment for RA with tocilizumab SC according to standard of care and in line with the current summary of product characteristics (SPC)/local labeling and who have no contraindication to tocilizumab therapy as per the local label are eligible for observation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Development of Transcutaneous Sensitization in Children With Atopic Dermatitis During Their First Year of Life

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. The severity of atopic dermatitis according to the EASI index (Eczema Area and Severity Index, index of prevalence and severity of eczema)\> 7 points (moderate and / or severe course of atopic dermatitis);~2. A burdened family allergic history (at least one of the parents has atopic dermatitis, food allergy, bronchial asthma and / or allergic rhinitis);~3. The presence of sensitization in the child to one or more of the studied food and household allergens, determined at the screening stage by the ImmunoCAP method: cow's milk protein, chicken egg protein, wheat, soy, hx2 house dust mixture: Dermatophagoides pteronyssinus, D. farinae, Blatella germanica .~Exclusion Criteria:~1. Use of topical calcineurin inhibitors (pimecrolimus) in the last 30 days prior to inclusion in the study;~2. A history of concomitant severe neurological, endocrinological, cardiovascular, hepatic and renal diseases;~3. The presence of acute bacterial, viral infections;~4. The child's lack of sensitization to detectable food and household allergens;~5. Clinically significant changes in the general analysis of urine, general analysis of blood, biochemical analysis of blood;~6. Refusal to sign an informed consent to participate in the study;~7. Inability to observe the patient during the study.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 4 Months
- Healthy Volunteers: f

Study Arms:
- Experimental group №1 (Type: EXPERIMENTAL): proactive therapy with local calcineurin inhibitors + emollients
- Experimental group №2 (Type: ACTIVE_COMPARATOR): proactive therapy with local glucocorticosteroids + emollients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete